Dengue vaccine-B cell and T cell responses linked to protection after controlled dengue infection
Official title: Analysis of innate responses and vaccination-induced serotype-specific B and T cell responses associated with protection against controlled human dengue virus challenge
Funded at Johns Hopkins University · NIH-11365993 · Data updated 2026-11-12
A Johns Hopkins-led study will look at how the body’s B and T cells respond to dengue vaccines and how these responses relate to protection against dengue infection in people who participate in a controlled infection model.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | June 1, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $766,437 |
| NIH project number | 1R01AI192605-01A1 |
| Project ID | NIH-11365993 on NIH RePORTER |
Who could benefit from this research
✓Could help
Healthy adults who participate in dengue vaccine studies and consent to follow-up immune analyses.
✕Less likely to help
Individuals who are not part of vaccine studies or who do not participate in the controlled infection model will not directly benefit.
What this research studies
This project will examine how vaccine-induced B cells, T cells, and innate immune responses relate to protection against dengue. Researchers will analyze specific B cell memory, antibody types, and T cell activity after vaccination and during a controlled dengue exposure in healthy volunteers to understand what immune features predict protection. The study uses samples from vaccine recipients to map serotype-specific responses and identify durable immune signatures that correlate with protection. Findings could guide the design of next-generation vaccines that provide balanced protection against all four dengue serotypes. The work is led by Johns Hopkins University and aims to inform vaccine strategies for U.S. service members and populations at risk worldwide.
Why it matters
Potential benefit: This research could inform the development of more effective dengue vaccines that provide robust, long-lasting protection against all serotypes.
How similar studies have gone: Previous work has shown that certain B cell and antibody responses correlate with protection, but this study aims to link those responses to actual protection in a controlled setting.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Bailey, Justin Richard — Johns Hopkins University
- Study coordinator: Bailey, Justin Richard
Related research
Other NIH-funded projects on the same topics.
-
Protective dengue vaccines that steer T and B cell responses
A vaccine study aims to guide the body’s T and B cells to fight all four dengue virus types safely and effectively.
-
How the immune system responds to dengue vaccines and infection
This project compares immune reactions in people given different dengue vaccine formulations to find why one vaccine fully prevented DENV-2 infection while another did not.
-
How prior dengue infections shape T cell responses after a new infection or vaccine
This project looks at how a person’s existing dengue immunity affects their body's T cell response when exposed to a different dengue serotype or a live dengue vaccine, with a focus on kids and how this influences protection and safety.
-
Protective immunity after dengue infections and vaccination
Researchers are studying how our immune system remembers dengue and how vaccines influence that protection, aiming to spot clues that predict who remains protected or at risk after infection or vaccination.
-
How long dengue vaccine protection lasts in areas where dengue is common
This project looks at immune responses after dengue vaccination to find which people keep protection longest in places where dengue is common.
-
How past dengue infection or vaccination shapes T cell immunity
This project looks at how previous dengue infections or a weakened dengue vaccine change T cells in children and others exposed to dengue.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.